Paper37101592
Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis.
Wang X and 5 others. TH Open, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis. Papers, record 37101592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37101592
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antithrombotic Effects of the Novel Small-Molecule Factor XIa Inhibitor Milvexian in a Rabbit Arteriovenous Shunt Model of Venous Thrombosis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30496103 | Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. | Lancet | 2018 | https://conductscience.org/library/papers/30496103 | PubMed |
| 2 | 18647224 | Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. | J Thromb Haemost | 2008 | https://conductscience.org/library/papers/18647224 | PubMed |
| 3 | 34780683 | Milvexian for the Prevention of Venous Thromboembolism. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34780683 | PubMed |
| 4 | 30700128 | Intrinsic Pathway of Coagulation and Thrombosis. | Arterioscler Thromb Vasc Biol | 2019 | https://conductscience.org/library/papers/30700128 | PubMed |
| 5 | 34752670 | Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits. | J Thromb Haemost | 2022 | https://conductscience.org/library/papers/34752670 | PubMed |
| 6 | 25084749 | Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model. | Thromb Res | 2014 | https://conductscience.org/library/papers/25084749 | PubMed |
| 7 | 26249722 | In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa. | J Thromb Thrombolysis | 2015 | https://conductscience.org/library/papers/26249722 | PubMed |
| 8 | 16839345 | Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. | J Thromb Haemost | 2006 | https://conductscience.org/library/papers/16839345 | PubMed |
| 9 | 15733058 | Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. | J Thromb Haemost | 2005 | https://conductscience.org/library/papers/15733058 | PubMed |
| 10 | 36768891 | Thrombosis Models: An Overview of Common In Vivo and In Vitro Models of Thrombosis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768891 | PubMed |
| 11 | 9518045 | A murine model of factor XI deficiency. | Blood Coagul Fibrinolysis | 1997 | https://conductscience.org/library/papers/9518045 | PubMed |
| 12 | 18945968 | Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. | Blood | 2009 | https://conductscience.org/library/papers/18945968 | PubMed |
| 13 | 17362226 | Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. | J Thromb Haemost | 2007 | https://conductscience.org/library/papers/17362226 | PubMed |
| 14 | 34297496 | Abelacimab for Prevention of Venous Thromboembolism. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34297496 | PubMed |
| 15 | 34494428 | Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy. | J Med Chem | 2022 | https://conductscience.org/library/papers/34494428 | PubMed |
| 16 | 12689935 | Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. | Blood | 2003 | https://conductscience.org/library/papers/12689935 | PubMed |
| 17 | 28373761 | Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. | World J Gastroenterol | 2017 | https://conductscience.org/library/papers/28373761 | PubMed |
| 18 | 25976012 | Factor XI and contact activation as targets for antithrombotic therapy. | J Thromb Haemost | 2015 | https://conductscience.org/library/papers/25976012 | PubMed |
| 19 | 10604970 | Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. | J Pharmacol Exp Ther | 2000 | https://conductscience.org/library/papers/10604970 | PubMed |
| 20 | 10706899 | High levels of coagulation factor XI as a risk factor for venous thrombosis. | N Engl J Med | 2000 | https://conductscience.org/library/papers/10706899 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42653793 | Translational Development of Oral FXIa Inhibitors: A Systematic Review of Molecular Design, Pharmacology, and Indication-Specific Clinical Evidence. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653793 | PubMed |
| 41549794 | A Thorough QT Study to Assess the Effects of Milvexian on Cardiac Repolarization in Healthy Participants. | Clin Pharmacol Drug Dev | 2026 | https://conductscience.org/library/papers/41549794 | PubMed |
| 39152241 | Milvexian: An Oral, Bioavailable Factor XIa Inhibitor. | Cardiol Ther | 2024 | https://conductscience.org/library/papers/39152241 | PubMed |
| 38374994 | Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors. | Front Cardiovasc Med | 2024 | https://conductscience.org/library/papers/38374994 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| F10 | 2159 | PubTator's text mining | https://conductscience.org/library/genes/2159 | NCBI Gene |
| F11 | 2160 | PubTator's text mining | https://conductscience.org/library/genes/2160 | NCBI Gene |
| F2 | 2147 | PubTator's text mining | https://conductscience.org/library/genes/2147 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37101592
GET https://conductscience.org/api/papers/v1/37101592/references?page=2